Cipla Limited — PPTs, 13-05-2026: Investor Presentation

Cipla reported its highest-ever yearly revenue of INR 28,163 Cr for FY26, a 2.2% increase year-on-year. However, net profit (PAT) for FY26 was INR 3,879 Cr, down 26.4% from the previous year, with EBITDA also declining 16.9% to INR 5,925 Cr. Q4FY26 saw revenue at INR 6,541 Cr and PAT at INR 555 Cr.

Key segments like One India, One Africa, and Emerging Markets & Europe showed double-digit growth in Q4FY26, with North America contributing 7% growth. A significant development includes the regulatory approval for its first AB-Rated gVentolin with CGT in North America, with launch expected soon. Cipla is also expanding through strategic alliances and acquisitions in Neuro/CNS and pediatrics.

The company maintains a strong net cash position of INR 11,140 Cr ($1 Bn+), earmarking these resources for future growth investments. It also made substantial progress on ESG goals, achieving an 83% reduction in Scope 1&2 emissions and becoming 2.6 times water positive in India manufacturing operations.